2[2]Simon LS.Role and regulation of cyclooxygenase-2 during inflammation.Am J Med,1999,106:37S-42S.
3[3]Lefkowith JB.Cyclooxygenase-2 specificity and its clinical implication.Am J Med,1999,106:43S-49S.
4[4]Henry D,Lim LYL,Rodriguez LAG,et al.Varibility in risk of gastrointestinal complications with individual nonsteroidal antiinflammatory drugs:results of a collaborative meta-analysis.BMJ,1996,312:1563-1566.
5[5]Van J,Botting J.selective COX-2 inhibitors:pharmacology,clinical effects and therapeutic potential.London:Dordrecht/Boton,1997.87-98.
6[6]Carrson JL,Wille L.Toxicity of nonsteroidal antiimflammatory drugs.Drugs,1993,46:243-248.
7[7]Churchill L,Graham AG,Shih C-K,et al.Selective inhibition of human cyclooxygenase-2 by meloxicam.Inflammopharmacology,1996,4:125-135.
8[8]Famaey JP.In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide:an overview.Inflamm Res,1997,46:437-442.
9[9]Lipsky LP,Abramson SB,Grofford L,et al.The classification of cyclooxygenase inhibitors.J Rheumatol,1998,25:2298-2303.
